Menu
image description

Category: LupusTrials.org

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […] Read More

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] Read More

Data Shows Voclosporin Preserves Kidney Function for Three Years

July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis.  These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […] Read More

Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia to Increase Diversity in Lupus Clinical Research

New York, NY. June 29. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the launch of three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. The sites selected to participate […] Read More

EULAR Presentation Showed Upadacitinib Improved Lupus Disease Activity

May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile.  Discovered and […] Read More

Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership

Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs  Washington, DC, March 29, 2023 – The Lupus Research Alliance (LRA) today announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. Food and Drug Administration (FDA), […] Read More

Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus […] Read More